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subjects, two each with diagnosis of non-small-cell lung 
cancer and sarcoma, treated at doses of 64 mg/m2 or higher, 
remained on study for 5–8 cycles.
Conclusions PNT2258 was safe and well tolerated at 
the doses tested up to 150 mg/m2. Exposure to PNT2258 
resulted in clinically manageable decreases in lymphocyte 
and platelet concentrations.
Keywords PNT2258 · Phase I · DNAi · 
Deoxyribonucleic acid inhibitor · BCL2 · Liposome
Introduction
BCL2 and its related family of proteins play a key and cen-
tral role during embryogenesis, homeostasis, as guardians 
of mitochondrial function, and in the regulation of apop-
tosis and autophagy subsequent to cellular injury or stress 
[1–3]. The derangement of BCL2 regulated control mecha-
nisms is a defining characteristic of certain malignancies 
including subsets of non-Hodgkin’s lymphoma (NHL) and 
chronic lymphocytic leukemia [4].
This phase 1 study is the first-in-human assess-
ment of PNT2258. The primary endpoints of the study 
included identification of the maximum tolerated dose 
of PNT2258 and characterization of the safety and tox-
icity profile of PNT2258 when administered to patients 
with advanced solid tumors. Secondary objectives 
included characterization of the PNT2258 pharmacoki-
netic profile and identification of any anti-tumor effect 
that may occur. The exploratory objective for the study 
included analysis of peripheral blood mononuclear 
cells (PBMCs), lymphocyte and platelet concentrations, 
plasma and serum samples for evidence of BCL2-medi-
ated effect.
Abstract 
Purpose Maximum tolerated dose, safety, pharmacoki-
netics, and pharmacodynamics were assessed in this phase 
1 study of PNT2258, a BCL-2-targeted liposomal formula-
tion of a 24-base DNA oligonucleotide called PNT100.
Methods Patients with malignant solid tumors were 
assigned sequentially to one of ten dose-escalation cohorts 
of PNT2258 at 1, 2, 4, 8, 16, 32, 64, 85, 113, and 150 mg/
m2 administered intravenously on days 1 through 5 of each 
21-day cycle. Pharmacokinetics were determined on days 
1 and 5 of the first cycle. Lymphocyte and platelets con-
centrations were measured for evidence of BCL2-targeted 
effect. CT scans were used to identify radiologic evidence 
of anti-tumor effect.
Results Twenty-two subjects received PNT2258, and the 
maximum tolerated dose for PNT2258 was not reached. 
Doses at or above 32 mg/m2 resulted in exposure to 
PNT2258 above the exposure level required for anti-tumor 
activity in preclinical xenograft testing of 22,377 ng h/
ml (PK analysis 2012). Fatigue was the most commonly 
reported adverse event. Dose-limiting toxicity, manifest-
ing as a transient increase in aspartate aminotransferase, 
occurred at 150 mg/m2, the highest dose tested. Four 
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PNT2258
PNT2258, the anti-BCL2 experimental therapeutic used in 
this study, consists of a protective liposomal formulation 
composed of four lipids encapsulating a 24-base, chemi-
cally unmodified DNA oligonucleotide called PNT100. 
A representation of the PNT2258 molecule is illus-
trated in Fig. 1a. The lipid components of this PNT2258 
nanoparticle are comprised of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE), cholesteryl 
hemisuccinate (CHEMS), and cholesteryl-4-([2-(4-mor-
pholinyl)ethyl]amino)-4-oxoburanoate (MOCHOL) [5]. 
These nanoparticles are anionic at physiological pH, and 
their specific lipid ratio imparts a “pH-tunable” character 
and a charge to the liposomes, which changes depending 
upon the surrounding pH of the microenvironment to facil-
itate movement across physiologic membranes [6, 7]. The 
PNT2258 nanoparticle is sized to avoid extensive hepatic 
sequestration, with an average diameter of approximately 
130 nm, facilitating systemic distribution and serum sta-
bility after intravenous injection [8]. These specialized 
liposomes are also known by the registered trade name as 
SMARTICLES®.
Preclinical studies of injected PNT2258 demonstrated 
systemic biodistribution of the active pharmaceutical ingre-
dient (PNT100) with accumulation into tissues including 
xenograft tumors [9].
PNT100
PNT100 is a single-stranded DNA 24-base oligonucleo-
tide encapsulated in the aqueous core within the liposomal 
nanoparticle. PNT100 is a solid-phase on-column chemi-
cally synthesized oligonucleotide that is cleaved from the 
column solid support, followed by ion-exchange (IEX) 
purification, ultra-filtration/diafiltration (UF/DF), and con-
centration with subsequent freeze-drying. PNT100 has the 
sequence, 5′-CACGCACGCGCATCCCCGCCCGTG-3′. 
PNT100 is specific to regulation of the BCL2 gene and not 
designed to hybridize to the regulatory areas of other BCL2 
protein family members such as Bcl-xL, MCL-1, or Bcl-w. 
HeLa cells exposed to Cy5.5-fluorescently labeled liposo-
mal encapsulated PNT100 showed fluorescence concen-
trated in nuclei with diffuse perinuclear distribution [10].
The PNT100 sequence is designed to hybridize with 
genomic sequences that reside within 5′-untranscribed 
regulatory regions of the BCL2 gene to block transcrip-
tion of BCL2 through a mechanism called DNA interfer-
ence (DNAi) (Fig. 1b). In cancerous cells and in contrast 
to normal cells, these upstream regulatory regions are sus-
ceptible to hybridization by having an open chromatin state 
that occurs during oncogene up-regulation [11]. Addition-
ally, the PNT100-targeted area of the genome is included 
in translocation t(14,18) [12]. The interaction of the 
PNT100 DNAi oligonucleotide with the targeted non-cod-
ing, non-transcribed genomic DNA was designed to block 
Fig. 1  a A representation of the PNT2258 molecule. The PNT100 
oligonucleotide is encapsulated in liposomes of MOCHOL/CHEMS/
DOPE/POPC, particle size ~130 nm. PNT2258 has an overall pKa 
of ~6.5, containing pH responsive lipids that are cationic during 
manufacturing (in order to attract the negatively charged PNT100 
oligonucleotide) and anionic during systemic circulation. Charge 
and lipid components are similar to circulating lipoproteins The pH 
“tunability” is designed to enhance endosomal escape following cel-
lular uptake. b Diagrammatic representation of the DNA “target” for 
PNT100 binding located on chromosome 18. The PNT100 oligonu-
cleotide sequence is designed to hybridize (i.e., bind) to a region 5′ 
upstream of the BCL2 gene start site
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transcription and silence BCL2 transcription, prompt-
ing initiation of the cell death pathway and pro-apoptotic 
events that lead to cancer cell death.
Preclinical studies
Liposomal formulations of PNT100 given IV have dem-
onstrated dose-dependent, single-agent efficacy, includ-
ing complete and partial tumor regressions and extended 
tumor growth delays in a WSU-DLCL2 murine xenograft 
model of human NHL [13]. In addition, synergistic in 
vivo anti-tumor effect was noted with liposomal PNT100 
in combination with rituximab or docetaxel in xenograft 
models of human Burkitt’s lymphoma and melanoma, 
respectively [8].
Anti-tumor effects in mice bearing WSU-DLCL2 NHL 
xenograft tumors were only observed when the animals 
received liposomal PNT100, but not a liposomal formu-
lation of either a scrambled 24-base control or a 2-base 
mismatch oligonucleotide (i.e., differing in sequence from 
PNT100 at 2-bases). These results suggest that a sequence-
specific genomic interaction contributed to the DNAi 
mechanism of action.
The preclinical pharmacokinetic characterization of 
PNT2258 consisted of analyzing PNT100 concentration, 
the active oligonucleotide ingredient in rodent and primate 
plasma obtained from a toxicity and safety pharmacol-
ogy study. In this study, PNT2258 was administered for 5 
consecutive days during two cycles separated by 2 weeks 
[14, 15]. PNT100 was detected by a hybridization-ligation 
assay after detergent disruption of the PNT2258-contain-
ing plasma samples. The probe used in the assay was spe-
cific for full-length human PNT100. The non-competitive 
hybridization and ligation assay (by ELISA) was validated 
in monkey plasma and cross-validated in human plasma 
(including interference for hemolysis) and was used in 
this study [16]. No free PNT100 was detected in the sam-
ples prior to detergent disruption of the lipid nanoparticle. 
The data obtained from measurement of monkey plasma 
PNT100 concentration demonstrated greater than dose-
proportional exposure and an apparent multi-compartmen-
tal and saturable clearance process. The clearance of the 
PNT2258 liposomes from circulation was presumed to be 
mediated by mononuclear phagocytes residing primarily 
in the spleen and liver (Kupffer cells) as visualized during 
histopathology in the toxicology studies in both cynomol-
gus monkeys and rats [14, 15, 17]. The tissue distribution is 
consistent with other known liposomal formulations [18].
Human study dose selection
In addition to the cynomolgus monkeys, rats were used as 
the second species for PNT2258 preclinical toxicity studies. 
A lowest no observed-adverse effect level (NOAEL) for 
PNT2258 was defined at 15 mg/kg/day in rats and 16 mg/
kg/day in monkeys. The IV starting dose of PNT2258 in 
the clinical phase 1 study was 1.0 mg/m2, representing 
1/6th the NOAEL in rats based on a corresponding human 
body surface area of 1.6 m2.
Materials and methods
Patient selection
The study population included only patients with meta-
static solid tumors that had exhausted standard therapeutic 
options; were age ≥18 years; and had Eastern Coopera-
tive Oncology Group performance status ≤2 with adequate 
bone marrow, hepatic, and renal function. As this was a 
pilot dose finding and toxicity-characterization phase 1 
study, pre-identification of patients on the basis of their 
existing BCL2 tumor status was not a requirement for 
study participation. All subjects provided written informed 
consent.
The trial was conducted in accordance with precepts 
established by the Helsinki Declaration. The institutional 
review board approved the protocol, and the study was reg-
istered at ClinicalTrials.gov and given the identifier number 
of NCT01191775 [19].
Study design and treatment schema
PNT2258 was supplied in 20 mL vials (with a target 
concentration of 2.5 mg/mL PNT100) and kept frozen 
(−20 ± 5 °C) during storage. PNT2258 was allowed to 
thaw at room temperature and subsequently diluted in 
200 mL of 0.9 % sodium chloride in preparation for IV 
administration. Patients received PNT2258 as a 2-hour IV 
infusion, once daily on days 1–5 of a 21-day cycle. Individ-
ual patient doses were calculated based upon body surface 
area (with capping at a maximum of 2 m2) obtained prior 
to dosing on C1D1 with an allowed adjustment in dose for 
≥10 % change in body weight during the study.
The initial dose level (i.e., cohort 1) was 1 mg/m2. Doses 
1 through 64 mg/m2 allowed 1 patient per cohort until the 
occurrence of a dose-limiting toxicity (DLT), triggering 
cohort expansion to 3 patients. Doses 85 through 150 mg/
m2 required 3 patients per cohort until the occurrence of a 
DLT. Assuming 0–1 DLTs at any dose level, patients were 
treated at the next higher dose level. If at any time 2 or 
more patients developed DLTs within a dose level, the level 
was considered too toxic, and the next lowest dose level 
was considered the recommended phase 2 dose.
All toxicities, regardless of attribution, were consid-
ered in determining whether a DLT had occurred at any 
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particular dose and DLT was defined as any of the follow-
ing events experienced during cycle 1: grade 4 neutropenia 
of >5 days duration or grade 3 or greater febrile neutrope-
nia of any duration; grade 4 thrombocytopenia; any grade 3 
or greater non-hematologic toxicity (except alopecia, nau-
sea/vomiting well controlled with antiemetics, and labora-
tory abnormalities felt to be clinically insignificant or that 
were elevated at baseline); any toxicity resulting in a treat-
ment delay of >2 weeks; an acute infusion reaction that did 
not resolve to baseline or ≤grade 1 after infusion interrup-
tion and resumption at a slower rate; a 2-grade increase in 
AST (SGOT)/ALT (SGPT) for patients with baseline grade 
1 or 2 abnormalities. The maximum tolerable dose (MTD) 
was defined prospectively as the dose level below the dose 
where ≥2 of 6 patients experienced DLT.
Sequential cohort doses were doubled (i.e., 1, 2, 4, 8, 16 
and 32 mg/m2) until the 64 mg/m2 dose level; thereafter, 
dose escalation proceeded in 33 % dose increments from 
85 to 113 mg/m2 and to a final dose of 150 mg/m2.
Baseline and treatment assessments
Baseline and on study assessments included medical his-
tory, physical examination, vital signs, ECOG performance 
status, ECG, radiographic tumor measurement, hematol-
ogy, clinical chemistry, urinalysis. Hematologic and non-
hematologic data were assessed according to the Common 
Terminology Criteria for Adverse Events (CTCAE) rating 
scale, version 3.0 [20]. Tumor response was assessed using 
Response Evaluation Criteria in Solid Tumors (RECIST) 
1.0 guidelines [21].
Pharmacokinetic and pharmacodynamic analyses
The concentration of encapsulated PNT100 was meas-
ured at predetermined sampling time points using the 
hybridization-ligation assay by Charles River Labs (Mon-
treal, Canada). Assay validation demonstrated specific-
ity, precision, accuracy, inter-assay variation, long-term 
stability, and no interference with 5 % (v/v) hemolysis 
in plasma with a lower limit of quantitation (LLOQ) of 
3 ng/mL [16].
A nonlinear mixed effect modeling technique (NON-
MEM, version VI) was used to analyze plasma PNT100 
data (log-transformed), allowing estimation of mean PK 
parameter values and inter-individual and intra-individual 
variability. Model parameters were estimated using the 
first-order conditional estimation method with interaction. 
The inter-individual and intra-individual variability were 
coded as an exponential and a proportional relationship, 
respectively. Three and 4 compartmental PK models with 
elimination from the peripheral compartment and a similar 
elimination rate constant were fitted to the PK data.
PNT100 plasma concentration data were also analyzed 
using a standard non-compartmental method to derive PK 
parameters for PNT100: maximum plasma concentration 
(Cmax), area under the plasma concentration versus time 
curve (AUC), and serum half-life (t1/2).
Lymphocyte and platelets concentrations were deter-
mined from patient samples obtained at prespecified time 
points throughout the study and analyzed per standard clin-
ical criteria.
Statistical analysis
Patient demographics, adverse events, clinical laboratory 
evaluations, and vital signs were summarized descriptively. 
Quantitative laboratory measurements were categorized 
according to normal reference ranges.
All patients that received PNT2258 were considered 
evaluable for the safety analysis. Patients that received at 
least 80 % of the planned dose in cycle 1 were considered 
evaluable for the purpose of dose escalation.
The efficacy-evaluable population included all patients 
with measurable disease that received at least one full cycle 
of PNT2258 and had at least one post-treatment response 
assessment or discontinued before having a response assess-
ment due to rapid disease progression or death. Descriptive 
statistics were used for plasma concentration data.
Results
Patients
Twenty-two patients were accrued and received PNT2258 
at START—South Texas Accelerated Research Therapeu-
tics, San Antonio, Texas, between September 2010 and 
January 2012. Table 1 summarizes patient demographics, 
disease characteristics, and prior treatment.
Treatment
Patients received PNT2258 at doses ranging from 1 to 
150 mg/m2, constituting over 300 doses and sixty 21-day 
cycles. Over all dose levels, patients received a median of 
2 completed cycles, with a range of 0–8 cycles. The most 
common reasons for study discontinuation were progres-
sive disease or symptomatic deterioration (19 patients, 
86 %). Two patients (9 %) discontinued therapy due to 
adverse event, and 1 patient (4 %) withdrew informed 
consent. Of the 335 planned doses of PNT2258, 314 were 
administered as scheduled. No patients were dose reduced 
for toxicity.
PNT2258 was well tolerated at dose levels 1 through 
64 mg/m2. A single patient manifested a grade 3 DLT of 
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back/flank pain while receiving the infusion at the 85 mg/
m2 dose level, triggering expansion of the cohort to six sub-
jects. After the occurrence of the DLT and at the discretion 
of the treating physician, subsequent patients could receive 
premedication prior to infusion with dexamethasone 
10 mg, diphenhydramine 50 mg, and ranitidine 50 mg IV, 
either alone or in combination, on day 1 of each cycle as 
prophylaxis for back/flank pain. This intervention limited 
additional occurrences of flank/back pain. No additional 
DLTs occurred at the 85 mg/m2 dose level or at 113 mg/m2. 
One DLT occurred at 150 mg/m2 manifesting as a grade 3 
increase in AST that resulted in expansion of the cohort. 
No additional cycle 1 DLTs were noted at the 150 mg/m2 
dose level. However, a patient developed a grade 4 throm-
bocytopenia within 30 days of study participation at the 
150 mg/m2 dose level.
Table 2 summarizes the drug-related toxicities at all 
dose levels. Across all dose levels and regardless of attri-
bution, a total of 79 adverse events and 6 serious adverse 
events (see section below) were reported. The most com-
mon AEs were fatigue (8 events in 7 subjects; 8/79, 10.1 %; 
grade range 1–2) and infusion reaction manifesting as back 
or flank pain (6 events in 4 subjects; 6/79; 7.6 %; grade 
range 2–3). The increase in aspartate aminotransferase at 
the 150 mg/m2 dose level was observed in a patient with 
metastatic disease to the liver and elevated levels resolved 
spontaneously within 48 h. One patient died, as a result of 
disease progression, within 30 days of study participation.
Efficacy
Of the 22 patients on study, 27 % (6 of 22) had stable 
disease at the time of the end-of-cycle 2 CT scan. Four 
patients, 2 each with a diagnosis of NSCLC at the 64 and 
85 mg/m2 dose levels and sarcoma at the 85 and 150 mg/
m2 dose levels, remained on study for >4 cycles (range 5–8 
cycles). See Fig. 2.
Pharmacokinetics
Plasma was obtained to evaluate the pharmacokinetics of 
PNT2258 (Table 3). Profiles were generated from C1D1 
and C1D5 dosing to calculate Cmax, t1/2, and AUC∞. Cmax 
values for C1D1 and C1D5 were consistent for dose 
cohorts with higher doses exhibiting an increase between 
C1D1 Cmax versus C1D5 Cmax and Cmax values in patients 
achieved at the higher dose levels approached those 
achieved in cynomolgus monkeys on C1D1.
Serum half-life (t1/2) could not be consistently calculated 
for C1D1 for dose cohorts 1–5, owing to rapid clearance 
kinetics of PNT2258 at these lower doses. t1/2 at the dose 
levels ≥32 mg/m2 ranged from 8.7 to 58.5 h. An increase in 
t1/2 over C1D1 was noted for C1D5. These results are con-
sistent with the expected prolonged clearance kinetics of 
PNT2258 due to saturation of the reticuloendothelial sys-
tem (RES) clearance mechanisms and are similar to those 
noted in the toxicology studies [14, 15, 17].
The results showed consistent Tmax of about 1.96 h, 
corresponding to the end of infusion sampling (data not 
shown).
A dose-dependent increase in AUC was noted with 
exposure levels in patients. In addition, a similar trend of 
increasing AUC was noted between C1D1 and C1D5 with 
AUCs in the latter sampling approaching those observed at 
the highest dose level tested in preclinical toxicology stud-
ies [22]. A less than dose-proportional increase was noted 
at the higher dose cohorts and may be indicative of achiev-
ing the maximum exposure of PNT2258.
Table 1  Patient demographics and disease characteristics
ECOG Eastern Cooperative Oncology Group
Parameter n = 22
Median age (range) 63 (30–91)
Gender, n (%)
 Male 12 (55)
 Female 10 (45)
Origin
 Caucasian 18 (82)
 African 2 (9)
 Hispanic 2 (9)
ECOG performance scale, n (%)
 0 3 (14)
 1 16 (72)
 2 3 (14)
Disease stage at entry, n (%)
 Stage IV 22 (100)
Pathologic diagnosis
 Pancreatic cancer 5
 Colon adenocarcinoma 5
 Sarcoma 3
 Prostate, adenocarcinoma 2
 Lung, non-small-cell carcinoma 2
 Breast, adenocarcinoma 1
 Endometrial 1
 Head and neck carcinoma 1
 Hepatocellular carcinoma 1
 Neuroendocrine tumor 1
Prior treatment
 Systemic therapy 22 (100)
 Surgery 17 (77)
 Radiotherapy 8 (36)
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The exposure levels (AUCs) in patients at doses 
at or above 32 mg/m2 (range 29,279–1,151,961 ng h/
ml) exceeded levels at which preclinical anti-
tumor effects were observed in xenograft studies 
(22,377 ng h/ml) [1, 22].
Pharmacodynamics
Figure 3a illustrates lymphocyte concentrations in patients 
receiving PNT2258. Maximum decrease and leveling of 
lymphocytes concentrations occurred within hours of the 
onset of PNT2258 infusion.
As shown in Fig. 3b, platelet levels decreased in patients 
after exposure to PNT2258 with nadir at approximately 
9 days post-onset of infusion. The decrease was generally 
≤grade 1 and transient in nature, with spontaneous resolu-
tion without the need for transfusion or other supportive 
measures and without evidence of bleeding diathesis.
Discussion
Progress in cancer therapeutics requires development and 
evaluation of novel strategies for drug delivery and inter-
ference of tumor cell signaling. One such novel strategy 
is the delivery of oligonucleotides into tumors in order to 
influence regulation of the cancer genome. PNT2258 is a 
first-in-class agent where a native unmodified DNA (24-
base) oligonucleotide is delivered to a nuclear genomic 
target via a protective liposomal nanoparticle and the first 
to target the regulatory upstream region of the BCL2 gene 
in this manner. Although other oligonucleotide constructs 
have been proposed and evaluated in clinic (although none 
targeting nuclear DNA), successful systemic delivery has 
been an issue and the complex chemical nature of these 
constructs has negatively influenced their clinical toxicity 
profile [7, 23]. DNA oligonucleotide-mediated suppression 
of genomic DNA (i.e., prior to transcription) could provide 
a more efficient and less toxic means of down-regulating 
oncogene expression and promotion of tumor killing when 
compared to standard cytotoxic therapy, post-translational 
targeting of mRNA (via RNA-based oligonucleotides), or 
Table 2  Treated patients (n = 22) with CTCAE 3.0 drug-related toxicitiesa
Gr grade, pts patients, no number, mg milligrams, m meter
a
 Listed adverse events are those assessed by the investigators as possible, probably or definitely related to study drug collected from the first 
dose of study drug until 30 days after discontinuation from the study. Patients are counted only once per event, with the highest experienced 
grade noted. No drug-related toxicity was reported in 2 or more patients at the 8 and 32 mg/m2 dose levels. Only toxicities reported in 2 or more 
patients over all cycles are reported with the exceptions stated below. A single grade 4 thrombocytopenia was noted during cycle 2 in the highest 
dose tested (i.e., 150 mg/m2). A single grade 3 toxicity of increased AST occurred at the 150 mg/m2 dose level





































Infusion reaction  
(i.e., back/flank  
pain)
1 (4) 1 (4) 1 (4) 2 (9) 1 (4) 6 (27)
Nausea 1 (4) 1 (4) 1 (4) 1 (4) 4 (18)
Vomiting 1 (4) 1 (4) 2 (9)
Diarrhea 1 (4) 1 (4) 2 (9)
Increased AST 1 (4) 1 (4)
Thrombocytopenia 1 (4) 1 (4)
Fig. 2  Days on study for each subject as a function of dose of 
PNT2258 administered. Patient cancer diagnosis is shown to the right 
of the bars
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the inhibition of proteins (via small molecule protein inhib-
itors) [7, 24–36]. Further, inhibition of proteins by small 
molecule inhibitors has resulted in “off-target” toxicity, as 
has been the case with other agents, including previously 
tested BCL2-targeted therapeutics [27, 29, 32, 34–42].
PNT2258, and other related DNAi molecules, allows 
for clinical examination of whether targeting the upstream 
“regulatory” areas of the tumor genome with DNA oligo-
nucleotides could be safe and tolerable and result in clinical 
activity without the characteristic toxicities of RNA-based 
oligonucleotides, cytotoxic, and small molecule protein 
inhibitor therapeutic approaches [43, 44].
This phase 1 study of PNT2258 allows for the following 
conclusions: (1) PNT2258 administered intravenously on 
days 1 through 5 of a 21-day cycle is well tolerated through 
doses of 150 mg/m2. (2) PNT2258 has an acceptable safety 
profile without evidence of thrombocytopenia or neutrope-
nia at the doses tested. (3) Pharmacologic studies confirmed 
that doses >32 mg/m2 resulted in human AUC levels above 
that required for anti-tumor effect in preclinical xenograft 
studies of BCL2-dependent tumors. (4) Human exposure 
levels exceeded that seen with other oligonucleotide drugs 
by 10–100-fold [45]. (5) PNT2258 administration resulted 
in decreases in lymphocyte and platelets counts, and (6) 
PNT2258 administration resulted in systemic delivery and 
was not restricted to the liver. Lastly, disease control was 
noted in 27 % (6 of 22) patients receiving PNT2258 as 
indicated by >2 cycles of disease stabilization in this treat-
ment-refractory population.
Preclinical results using human tumor xenograft-bearing 
mice confirmed robust single-agent anti-BCL2 response 
in the WSU-DLCL model, a NHL line with t(14,18) [13]. 
Given the relatively wide dose range between the corre-
sponding minimally effective exposure in the xenograft 
model (i.e., the 32 mg/m2 dose level in humans) and the 
maximum tested dose of 150 mg/m2, it suggests that addi-
tional PNT2258 doses and schedules could be explored in 
Table 3  PNT2258 plasma pharmacokinetic parameters following day 1 and 5 dosing (2-hour IV infusion)
Numbers in parentheses indicate coefficient of variation (%). – indicates data not available
AUC∞, area under the concentration–time curve from zero to infinity; Cmax, peak (maximum) plasma concentration; t1/2, half-life; IV, intrave-
nous
Dose mg/m2 Day 1 Day 5
No. of patients Cmax (ng/mL) T1/2 (h) AUC∞ (ng h/mL) No. of patients Cmax (ng/mL) T1/2 (h) AUC∞ (ng h/mL)
1 1 15.87 334.4 1,559 1 14.09 – –
2 1 28.02 – – 1 32.24 47.1 1,313
4 1 39.55 – – 1 98.30 82.2 7,404
8 1 132.26 74.1 1,888 1 97.10 46.0 2,550
16 1 317.33 – – 1 522.36 45.1 6,731
32 1 894.32 21.9 29,279 1 2,477.54 58.5 131,853
64 1 5,306.63 10.9 57,543 1 8,141.03 35.1 193,421
85 6 7,895 (35) 27.8 (73) 146,685 (67) 6 12,311 (54) 50.3 (27) 607,765 (75)
113 3 29,222 (40) 10.2 (42) 204,148 (61) 3 42,125 (91) 32.1 (26) 849,077 (123)
150 6 28,943 (39) 8.7 (57) 203,879 (49) 6 35,926 (43) 26.8 (47) 1,151,961 (60)
Fig. 3  a First-cycle lymphocyte nadir (i.e., percent maximum decline 
from baseline) as a function of dose. b Cycle 1 platelet levels
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addition to the one reported here. There were no clinically 
unmanageable grade 3 or 4 toxicities, even in this heavily 
pre-treated population at any dose level tested.
This intravenously administered agent displayed favora-
ble pharmacologic features with relatively long (i.e., 
1–2 day) half-life consistent with the goal of maximum 
exposure of the DNA-containing liposome nanoparticle to 
all tissues in the body and without evidence of cumulative 
toxicity secondary to the 5-day infusion schedule or evi-
dence of significant hepatic sequestration.
While patients entering this pilot phase 1 trial of 
PNT2258 were not subjected to biopsy and therefore not 
preselected on the basis of their BCL2 expression status, 
the results of this trial are encouraging and indicate a need 
for further exploration of PNT2258 in patients diagnosed 
with BCL2-dependent tumors. On the basis of the results of 
this study, a phase 2 study (NCT01733238) has been initi-
ated to explore the utility of PNT2258 as a single agent in 
patients with relapsed or refractory NHL.
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